Aquestive Therapeutics (AQST) Net Income towards Common Stockholders (2017 - 2026)

Aquestive Therapeutics' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 64.86% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$68.9 million (down 27.05% YoY), while the FY2025 annual figure was -$83.8 million, down 89.83% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$8.1 million, up from -$31.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $8.1 million in Q1 2023, with the low at -$31.9 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$12.5 million (2022), against an average of -$11.7 million.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 161.03% in 2023, then tumbled 465.55% in 2024.
• Aquestive Therapeutics' Net Income towards Common Stockholders stood at -$12.4 million in 2022, then soared by 34.33% to -$8.1 million in 2023, then tumbled by 110.27% to -$17.1 million in 2024, then slumped by 86.81% to -$31.9 million in 2025, then jumped by 74.71% to -$8.1 million in 2026.
• Business Quant data shows AQST's Net Income towards Common Stockholders at -$8.1 million in Q1 2026, -$31.9 million in Q4 2025, and -$15.4 million in Q3 2025.